Amgen stock holds above $415 as strong Q2 2026 results lift guidance
Published on 08/13/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (ISIN US0311621009) stock is trading in the mid-$410s as of August 12, 2026, supported by strong second quarter 2026 results and a higher full-year revenue and earnings outlook. Per a detailed Q2 2026 earnings overview dated August 13, 2026, Amgen delivered solid growth across its portfolio and lifted guidance for fiscal 2026 in response to that momentum. For investors, the combination of double-digit revenue growth and a higher earnings range provides a clearer picture of Amgen's trajectory for the rest of the year.
Q2 2026 earnings show double-digit growth
An in-depth analysis of Amgen's Q2 calendar 2026 performance reports that total revenue for the quarter reached $10.05 billion, with year-on-year growth of 9.5% compared with the same period in 2025. A Q2 CY2026 highlights summary notes that this $10.05 billion figure exceeded analyst estimates of $9.40 billion, representing a revenue beat of $0.65 billion or 6.9% against consensus expectations.
The same Q2 CY2026 overview indicates that adjusted earnings per share for the quarter came in at $6.29, compared with analyst estimates of $5.62. This implies Amgen beat the Q2 2026 adjusted EPS consensus by $0.67 per share, a positive surprise of 12% versus expectations. In addition, adjusted operating income was reported at $4.61 billion on the quarter, with an operating margin of 45.9% that surpassed analyst estimates of $4.15 billion and reflected an 11.1% beat on that metric.
Alongside these headline figures, another Q2 2026 earnings call transcript dated August 13, 2026 states that Amgen's management now expects full-year 2026 total revenues in the range of $38.2 billion to $39.4 billion, raised from a previous range that was lower at the midpoint. The Q2 2026 earnings call transcript indicates that non-GAAP earnings per share guidance for fiscal 2026 has also been increased to a range of $22.30 to $23.50, reflecting improved confidence based on double-digit revenue growth in the first half.
Guidance raised and portfolio momentum
Within the Q2 CY2026 highlights analysis, management commentary emphasizes that 22 products achieved double-digit sales growth in the quarter, and that 17 products are annualizing over $1 billion in sales. This breadth across the portfolio supports the raised 2026 guidance, as the updated full-year revenue range of $38.2 billion to $39.4 billion implies mid-single-digit to high-single-digit growth depending on the final outcome.
The same Q2 CY2026 summary notes that Amgen lifted its revenue guidance for the full year to $38.8 billion at the midpoint from $37.8 billion previously, an increase of $1.0 billion or 2.6% in the midpoint expectation. On the earnings side, the analysis highlights that the company raised its full-year adjusted EPS guidance to $22.90 at the midpoint, up from an earlier midpoint that was 2.2% lower, signaling that operating leverage and product mix are feeding through to higher profit expectations.
In the Q2 2026 earnings call transcript, management outlines capital expenditure plans of $2.6 billion for 2026, focused heavily on expanding manufacturing capacity for weight management products and other high-growth therapies. The same document states that total capital expenditures of $2.6 billion for the year will support scaling volume for launches such as the weight management drug candidate MariTide, as well as investments across manufacturing and supply chain. In addition, the transcript mentions planned share repurchases capped at $3.0 billion for the full fiscal year 2026 and notes dividend payments of $2.52 per share in the second quarter, representing a 6% increase compared with Q2 2025.
Analyst context and valuation discussion
A separate valuation-focused article dated August 13, 2026 evaluates whether Amgen is fully valued after its strong Q2 results and raised 2026 guidance. The valuation analysis notes that at a last close of $416.18, Amgen screens as priced above a narrative fair value estimate of $359.98, implying a premium of $56.20 per share or roughly 15.6% compared with that fair value benchmark. The article frames this premium as a reflection of investor expectations for continued execution on the raised guidance and ongoing growth in key therapeutic areas.
From an investor perspective, the combination of a raised revenue guidance range, higher non-GAAP EPS expectations, and a valuation premium against a fair value model suggests that the market is willing to pay up for Amgen's growth profile. With a reported operating margin of 35% for the quarter, up from 28.9% in the same quarter a year earlier according to the Q2 CY2026 highlights overview, Amgen is also showing clear margin expansion. The 6.1 percentage point increase in operating margin underlines an improving efficiency and revenue mix that can support higher earnings even as the company invests in manufacturing capacity.
Read more on Amgen stock
Go deeper
For investors interested in exploring Amgen's broader investor relations materials, presentations and filings, the company maintains a dedicated investor portal. This investor information portal provides access to earnings presentations, SEC filings and detailed information on Amgen's strategy, pipeline and capital allocation policies, complementing the Q2 2026 results and guidance discussed above.
More on Amgen stock
Amgen's latest earnings details and guidance updates highlight how the company is balancing growth investments in weight management and other innovative therapies with shareholder returns through dividends and measured buybacks, offering a comprehensive picture of the stock's risk-reward profile in 2026.
Weight management and key products
In the Q2 2026 earnings call materials, Amgen describes continued investment in weight management therapies, including the development and planned launch of a product referred to as MariTide. The capital expenditure guidance of $2.6 billion for 2026, as detailed in the earnings call transcript, is explicitly tied to scaling manufacturing capacity for weight management products, reflecting confidence in demand for this segment.
At the same time, the Q2 CY2026 highlights analysis underscores that double-digit sales growth across multiple cardiovascular, bone health and respiratory products contributed to the overall revenue beat. While individual product sales are not fully broken out in the snippets available, the commentary indicates that a group of six key growth drivers now accounts for nearly 70% of total product sales, reinforcing the strategic importance of these therapies in Amgen's portfolio.
Stock price and market data
For market data as of the most recent completed trading session, a real-time quote page updated on August 13, 2026 shows Amgen Inc. shares at a closing price of $415.84 on August 12, 2026, with a daily gain of 0.37% on that session. The real-time stock quote overview reports that the stock closed at $415.84, up $1.54 on the day, translating to that 0.37% increase versus the prior close.
The same market-data overview indicates that Amgen's market capitalization stands at $224.80 billion as of August 12, 2026, based on the latest share price and shares outstanding. Using the EPS trailing twelve months figure of 14.49 cited in the same source, the trailing price-to-earnings ratio would be approximately 28.7, reflecting how the market is valuing Amgen's earnings stream ahead of the raised 2026 guidance. Another news and forecast page focused on Amgen confirms the closing price of $416.18 on August 12, 2026, consistent with the trading range indicated by the various quote snapshots.
From a technical perspective, these price levels place Amgen stock above the narrative fair value estimate discussed in the valuation article, and on a trajectory aligned with the raised guidance narrative. While detailed 52-week high and low figures are not fully visible in the current excerpts, the mid-$410s price range suggests the shares are trading toward the upper portion of recent ranges compiled by market-data services.
Representative therapy in Amgen's portfolio
One representative area of Amgen's business is weight management, where the company is advancing the candidate therapy MariTide as highlighted in the Q2 2026 earnings call transcript. MariTide is cited in that transcript in the context of capital expenditure plans, with management stating that the company expects capital expenditures of $2.6 billion in 2026 in order to expand manufacturing capacity for volume growth, including for MariTide's launch. This places the therapy at the center of Amgen's growth investment plans for the current year.
By channeling significant capital into the manufacturing and supply chain infrastructure needed to scale MariTide and other growth drivers, Amgen is positioning itself to capture emerging demand in the weight management space. That strategic decision ties directly into the raised revenue and earnings guidance ranges for 2026, as the company anticipates volume growth from these new therapies will help sustain double-digit revenue increases and margin expansion over time.
Closing view on Amgen stock
As of August 12, 2026, at the close of regular trading hours, Amgen stock trades at $415.84 on the Nasdaq, giving the company a market capitalization of $224.80 billion based on recent market data reports. This price level stands modestly above the $359.98 narrative fair value cited in a valuation review, highlighting that investors are assigning a premium to Amgen's shares in light of strong Q2 2026 results and higher full-year guidance.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 12, 2026, 4:00 p.m. ET): $415.84 USD
Market cap: $224.80 billion (as of August 12, 2026)
Sector / Industry: Biotechnology
Index membership: S&P 500
